Dissolution Problems Prompt Recall by Dr. Reddy's
Dr. Reddy's recalls blood pressure drug due to failed dissolution tests.
FDA has reported that Dr. Reddy’s Laboratories has initiated a voluntary recall for Metoprolol Succinate Extended Release Tablets, USP 25 mg, 100-count bottle for failed dissolution specifications.
The recall, initiated on May 23, 2014, involves 13,560 bottles, was for failure of a dissolution test observed at an 18-month time point and involved two lots.
FDA classified the recall as Class II, a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Source: FDA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
